Vaccine for treating mRNA-DC lung cancer, enhanced preparation method of vaccine and CTL cell

Abstract

The invention provides a vaccine for treating mRNA-DC lung cancer and an enhanced preparation method of the vaccine. The method includes the steps of obtaining mRNA, IL-2 and IFN-gamma of a lung cancer stem cell, and transfecting the mRNA, the IL-2 and the IFN-gamma into DC to be cultivated in vitro. According to the method process, based on the technological foundation that the DC can receive and translate the external mRNA and codon has universality, the DC is stimulated through the method that antigen proteins are expressed after the mRNA of the lung cancer stem cell is guided in and replace inactivated proteins for stimulation, and the carried antigen information is more comprehensive; the defect that due to inactivation, breakage and the like of the externally-stimulated antigen proteins, the antigen information is lost can be overcome; meanwhile, the IL-2 and the IFN-gamma are transfected into the DC, then the mature induction can be started in the immune response process, the induction time in an ordinary culture medium can be greatly shortened, the cell maturation efficiency is improved, and immune responses are enhanced. The invention further provides a cytotoxic T lymphocyte obtained by co-culturing the vaccine for treating mRNA-DC lung cancer and a T lymphocyte.

Description

technical field [0001] The invention belongs to the technical field of cellular immunotherapy, and in particular relates to an mRNA-DC lung cancer therapeutic vaccine, a preparation method thereof and CTL cells. Background technique [0002] The adoptive immunotherapy for lung cancer is to induce, activate and amplify the precursor cells of self or allogeneic anti-tumor effector cells in vitro with activators such as IL-2, anti-CD3 monoclonal antibody, and specific polypeptides, and then transfect Infuse it to tumor patients, so as to improve the anti-tumor immunity of patients, so as to achieve the purpose of treatment. Currently, the adoptive immune cells most used in clinical practice are mainly DC (dendritic cell, dendritic cell) and CIK (Cytokine-Induced Killer, cytokine-induced killer cell). [0003] Among them, DC is isolated from bone marrow tissue and blood, has strong ability to capture antigen, present antigen and secrete ability, and can induce a lasting and pow...

AI Technical Summary

Problems solved by technology

However, there are deficiencies in this way of antigen stimulation. First, the antigen information carried by lung cancer cells is incomplete compared with the overall antigen information of lung cancer, and only a part of the antigen information can be transmitted to DC; second, the production of a certain protein is not enough. If, or if some broken proteins are produced, the antigenicity will be further reduced; thirdly, because the expansion ability of lung cancer cells is much stronger than that of DCs, in order to avoid the growth inhibition of DCs caused by lung cancer cells in DC culture, it is ultimately impossible to harvest In the case of DC, DCs need to be inactivated before being stimulated, and many antigen clusters are destroyed during the inactivation; therefore, the adoptively immunized DCs cultured for lung cancer have a weak immune response and a weak tumor killing ability.

Images